Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2021 Aug 30

PMID 34459898

Citations 18

Authors

Matthew C Riddle

William T Cefalu

Philip H Evans

Hertzel C Gerstein

Michael A Nauck

William K Oh

Amy E Rothberg

Carel W le Roux

Francesco Rubino

Philip Schauer

Roy Taylor

Douglas Twenefour

Affiliations

Soon will be listed here.

Abstract

Improvement of glucose levels into the normal range can occur in some people living with diabetes, either spontaneously or after medical interventions, and in some cases can persist after withdrawal of glucose-lowering pharmacotherapy. Such sustained improvement may now be occurring more often due to newer forms of treatment. However, terminology for describing this process and objective measures for defining it are not well established, and the long-term risks versus benefits of its attainment are not well understood. To update prior discussions of this issue, an international expert group was convened by the American Diabetes Association to propose nomenclature and principles for data collection and analysis, with the goal of establishing a base of information to support future clinical guidance. This group proposed "remission" as the most appropriate descriptive term, and HbA1c < 6.5% (48 mmol/mol) measured at least 3 months after cessation of glucose-lowering pharmacotherapy as the usual diagnostic criterion. The group also made suggestions for active observation of individuals experiencing a remission and discussed further questions and unmet needs regarding predictors and outcomes of remission.

Citing Articles

Cost-effectiveness of a digital supportive healthcare pathway for type 2 diabetes compared to usual care in Belgium.

Van Wilder L, De Smedt D, Sandra L, Vandormael D, Kaes J, Willems R Digit Health. 2025; 11:20552076251319169.

PMID: 40017608 PMC: 11866382. DOI: 10.1177/20552076251319169.

Effectiveness of internet-based management in newly diagnosed young adults with type 2 diabetes: a prospective comparative study.

Li Z, Luo D, Li Z Endocr Connect. 2025; 14(4).

PMID: 39952231 PMC: 11877641. DOI: 10.1530/EC-24-0576.

Effects of Personalized DiaBetes TEXT Messaging Combined with Peer Support Education on Patients With Type 2 Diabetes: A Randomized Controlled Trial.

Romadlon D, Huang H, Chen Y, Hu S, Kurniawan R, Tarigan T J Diabetes Sci Technol. 2025; :19322968251314501.

PMID: 39881449 PMC: 11780624. DOI: 10.1177/19322968251314501.

Diabetes remission in newly diagnosed type 2 diabetes mellitus through short-term continuous subcutaneous insulin infusion intensive therapy combined with low-carbohydrate diet treatment.

Huang X, Jiang J, Liu L, Lin Y, Zhang F, Ling X J Diabetes Investig. 2024; 16(3):426-433.

PMID: 39610089 PMC: 11871405. DOI: 10.1111/jdi.14371.

Targeting the Gut Microbiota for Prevention and Management of Type 2 Diabetes.

Donati Zeppa S, Gervasi M, Bartolacci A, Ferrini F, Patti A, Sestili P Nutrients. 2024; 16(22).

PMID: 39599740 PMC: 11597803. DOI: 10.3390/nu16223951.

References

Shah V, DuBose S, Li Z, Beck R, Peters A, Weinstock R . Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. J Clin Endocrinol Metab. 2019; 104(10):4356-4364. PMC: 7296129. DOI: 10.1210/jc.2018-02763. View

. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998; 116(7):874-86. DOI: 10.1001/archopht.116.7.874. View

Schauer P, Bhatt D, Kirwan J, Wolski K, Aminian A, Brethauer S . Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med. 2017; 376(7):641-651. PMC: 5451258. DOI: 10.1056/NEJMoa1600869. View

Murphy R, Jiang Y, Booth M, Babor R, MacCormick A, Hammodat H . Progression of diabetic retinopathy after bariatric surgery. Diabet Med. 2015; 32(9):1212-20. DOI: 10.1111/dme.12727. View

Currie C, Peters J, Tynan A, Evans M, Heine R, Bracco O . Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010; 375(9713):481-9. DOI: 10.1016/S0140-6736(09)61969-3. View

Lim E, Hollingsworth K, Aribisala B, Chen M, Mathers J, Taylor R . Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011; 54(10):2506-14. PMC: 3168743. DOI: 10.1007/s00125-011-2204-7. View

Yki-Jarvinen H . Glucose toxicity. Endocr Rev. 1992; 13(3):415-31. DOI: 10.1210/edrv-13-3-415. View

Danne T, Nimri R, Battelino T, Bergenstal R, Close K, DeVries J . International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017; 40(12):1631-1640. PMC: 6467165. DOI: 10.2337/dc17-1600. View

Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes A, Aribisala B . Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. Cell Metab. 2018; 28(4):667. DOI: 10.1016/j.cmet.2018.08.010. View

10.

Barnes E . Between remission and cure: patients, practitioners and the transformation of leukaemia in the late twentieth century. Chronic Illn. 2007; 3(4):253-64. DOI: 10.1177/1742395307085333. View

11.

Jeppsson J, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T . Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002; 40(1):78-89. DOI: 10.1515/CCLM.2002.016. View

12.

. EurA1c: The European HbA1c Trial to Investigate the Performance of HbA1c Assays in 2166 Laboratories across 17 Countries and 24 Manufacturers by Use of the IFCC Model for Quality Targets. Clin Chem. 2018; 64(8):1183-1192. DOI: 10.1373/clinchem.2018.288795. View

13.

Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Capristo E . Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021; 397(10271):293-304. DOI: 10.1016/S0140-6736(20)32649-0. View

14.

Buse J, Caprio S, Cefalu W, Ceriello A, Del Prato S, Inzucchi S . How do we define cure of diabetes?. Diabetes Care. 2009; 32(11):2133-5. PMC: 2768219. DOI: 10.2337/dc09-9036. View

15.

McInnes N, Smith A, Otto R, Vandermey J, Punthakee Z, Sherifali D . Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. J Clin Endocrinol Metab. 2017; 102(5):1596-1605. DOI: 10.1210/jc.2016-3373. View

16.

Simmons L, Molyneaux L, Yue D, Chua E . Steroid-induced diabetes: is it just unmasking of type 2 diabetes?. ISRN Endocrinol. 2012; 2012:910905. PMC: 3398625. DOI: 10.5402/2012/910905. View

17.

Rubino F, Nathan D, Eckel R, Schauer P, Alberti K, Zimmet P . Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016; 39(6):861-77. DOI: 10.2337/dc16-0236. View

18.

Gregg E, Chen H, Wagenknecht L, Clark J, Delahanty L, Bantle J . Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2013; 308(23):2489-96. PMC: 4771522. DOI: 10.1001/jama.2012.67929. View

19.

Lean M, Leslie W, Barnes A, Brosnahan N, Thom G, McCombie L . Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019; 7(5):344-355. DOI: 10.1016/S2213-8587(19)30068-3. View

20.

Kramer C, Zinman B, Choi H, Retnakaran R . Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diabetes Res Care. 2016; 4(1):e000270. PMC: 4985916. DOI: 10.1136/bmjdrc-2016-000270. View